Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Clinical trial NCT04377932 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04377932
Sponsor: Baylor College of Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Liver Cancer Rhabdomyosarcoma Malignant Rhabdoid Tumor Liposarcoma Wilms Tumor Yolk Sac Tumor

Start date: 2021-08-08
Primary completion: 2024-08-17
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.